BioPharmX Corporation (BPMX) Expected to Announce Earnings of -$0.01 Per Share

Share on StockTwits

Equities research analysts predict that BioPharmX Corporation (NASDAQ:BPMX) will announce earnings of ($0.01) per share for the current fiscal quarter, according to Zacks. Zero analysts have issued estimates for BioPharmX’s earnings. BioPharmX posted earnings per share of ($0.02) during the same quarter last year, which would indicate a positive year over year growth rate of 50%. The business is expected to report its next quarterly earnings report on Thursday, June 6th.

According to Zacks, analysts expect that BioPharmX will report full year earnings of $0.05 per share for the current fiscal year, with EPS estimates ranging from ($0.04) to $0.13. For the next financial year, analysts expect that the company will report earnings of ($0.03) per share. Zacks Investment Research’s EPS calculations are an average based on a survey of research firms that that provide coverage for BioPharmX.

BioPharmX (NASDAQ:BPMX) last issued its quarterly earnings results on Thursday, March 14th. The company reported ($0.01) earnings per share for the quarter, topping the consensus estimate of ($0.02) by $0.01. The business had revenue of $0.01 million during the quarter.

Shares of NASDAQ BPMX opened at $0.09 on Friday. BioPharmX has a fifty-two week low of $0.05 and a fifty-two week high of $0.29.

About BioPharmX

BioPharmX Corporation, a specialty pharmaceutical company, develops and commercializes novel prescription and over-the-counter (OTC) products that address dermatology and women's health markets. The company offers VI2OLET, an OTC molecular iodine dietary supplement that addresses cyclic breast discomfort, as well as alleviates the symptoms of fibrocystic breast condition (FBC).

Read More: How Does the Quiet Period Work?

Get a free copy of the Zacks research report on BioPharmX (BPMX)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for BioPharmX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioPharmX and related companies with's FREE daily email newsletter.